华东医药：注射用HDM2017药品临床试验申请获美国FDA批准

Core Viewpoint - The company has received FDA approval for its clinical trial application for the injectable drug HDM2017, which will be used for Phase I clinical trials in the United States targeting advanced malignant solid tumors [1] Company Summary - The full subsidiary of the company, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., is responsible for the application that received FDA approval [1] - The approved clinical trial will focus on advanced malignant solid tumors, indicating a strategic move into the oncology market [1]